A Newark-based biotech company announced progress in obtaining two patents in Europe. IBio Inc., which is based at the Delaware Technology Park, was granted permission to proceed with two patents that make use of plant-based innovations, the company said in a statement Thursday.
This was one of several announcements made by the publicly traded company (IBIO) in recent weeks. On Tuesday, the business announced a $10 million common stock purchase agreement with Aspire Capital. And on Aug. 14 they released information about a partnership between iBio and Kanematsu Chemicals Corporation, which will allow them to market the product iBioLaunch in Japan. The iBioLauch innovation was developed to allow for a more nimble means for new drugs so they can reach the marketplace faster.
The iBio company was founded at the Delaware Biotechnology Institute, which is a partnership between private business, government and higher education. It is based at the Delaware Technology Park on Innovation Way in Newark.
Shares of iBio were trading at 48 cents on Friday. The 52-week range for shares of IBIO stock was 24 cents to 85 cents, according to Yahoo Finance.
Nichole Dobo, The News Journal